Should You Buy Surgery Partners, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Surgery Partners, Inc. (SGRY) carries a solid Quality of Company rating of 6.4/10. Trading at $16.03, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 3 of 11 CirclFi valuation models project upside for Surgery Partners, Inc. (SGRY) at $16.03 — the model consensus leans bearish, with a Quality Score of 6.4/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $25.28 (+57.7% upside)
- According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model targets a fair value of $25.28 (+57.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
The Bear Case
Target: $1.96 (-87.8%)
- According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $1.96 (-87.8%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +145.5% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
The Bottom Line
Caution dominates our read on Surgery Partners, Inc. at $16.03. 7 of 11 models see limited upside or outright downside, with the composite fair value at $10.86 (-32.3%). Quality at 6.4/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Surgery Partners, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy SGRY stock right now?
Based on CirclFi's multi-model analysis, 3 of 11 models see upside for SGRY at $16.03. The models are divided, which means the investment case depends heavily on your assumptions about Surgery Partners, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Surgery Partners, Inc.?
Key risks include: wide model disagreement (1191% spread), signaling high uncertainty; general market and sector-specific risks affecting Services-General Medical & Surgical Hospitals, NEC companies. Always diversify and consult a financial advisor.
How does SGRY compare to its competitors?
Among Services-General Medical & Surgical Hospitals, NEC peers, SGRY holds a Quality Score of 6.4/10. Comparable companies include ARDT (QOC 9.1), UHS (QOC 9.0), HCA (QOC 8.2). The relative ranking helps investors identify whether SGRY offers better fundamental quality than alternatives in the same sector.
Is SGRY a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. SGRY's Quality Score of 6.4/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy SGRY at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $1.96 to $25.28. At $16.03, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for SGRY.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad